期刊
JOURNAL OF NEURAL TRANSMISSION
卷 123, 期 1, 页码 3-17出版社
SPRINGER WIEN
DOI: 10.1007/s00702-015-1443-z
关键词
Parkinson's disease; Internal disease; Comorbidity; Side effects; Interactions
资金
- Abbvie
- Desitin
- Medtronic
- TEVA
- UCB Pharma
- Zambon
- Abbott
- Bayer Health Care
- Boehringer/Ingelheim
- Brittania
- Cephalon
- GSK
- Lundbeck
- Merck-Serono
- Novartis
- Orion
- Pfizer
- Valeant
General medical problems and complications have a major impact on the quality of life in all stages of Parkinson's disease. To introduce an effective treatment, a comprehensive analysis of the various clinical symptoms must be undertaken. One must distinguish between (1) diseases which arise independently of Parkinson's disease, and (2) diseases which are a direct or indirect consequence of Parkinson's disease. Medical comorbidity may induce additional limitations to physical strength and coping strategies, and may thus restrict the efficacy of the physical therapy which is essential for treating hypokinetic-rigid symptoms. In selecting the appropriate medication for the treatment of any additional medical symptoms, which may arise, its limitations, contraindications and interactions with dopaminergic substances have to be taken into consideration. General medical symptoms and organ manifestations may also arise as a direct consequence of the autonomic dysfunction associated with Parkinson's disease. As the disease progresses, additional non-parkinsonian symptoms can be of concern. Furthermore, the side effects of Parkinson medications may necessitate the involvement of other medical specialists. In this review, we will discuss the various general medical aspects of Parkinson's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据